Reported a net loss of $7.6 million for the three months ended March 31, 2026, compared to $5.5 million in the same period of 2025. Cash and restricted cash totaled $4.1 million as of March 31, 2026. The company is operating under a going concern warning, relying on debt advances from Hanmi Pharmaceutical to fund operations. Shareholders approved a Plan of Arrangement on March 31, 2026, for Hanmi to acquire all outstanding common shares for C$2.41 per share. The acquisition is expected to close in May 2026, subject to customary closing conditions and regulatory approvals.